{
"id":"mk19_b_hm_s3",
"subspecialtyId":"hm",
"title":"Multiple Myeloma and Related Disorders",
"jsonContent":{
"type":"section",
"id":"mk19_b_hm_s3",
"title":{
"__html":"Multiple Myeloma and Related Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"e65ce6",
"children":[
"Multiple Myeloma and Related Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s3_1",
"title":{
"__html":"Overview"
},
"titleNode":{
"type":"section-title",
"hlId":"3b8782",
"children":[
"Overview"
]
},
"children":[
{
"type":"p",
"hlId":"0c0774",
"children":[
"B-cell maturation to plasma cells involves antigen-independent and antigen-dependent phases. When humoral immunity is stimulated (infection or inflammation), multiple clones of plasma cells are expanded and produce immunoglobulins of different classes and specificity, giving the polyclonal spike seen on protein electrophoresis. In contrast, plasma cell dyscrasias (PCDs) or monoclonal gammopathies are a clonal expansion of the plasma cell or lymphoplasmacytic cell, which produces a uniform monoclonal spike (M spike) on protein electrophoresis. This monoclonal (M) protein can be a complete immunoglobulin, with a heavy chain (IgG, IgA, IgD, or IgM) complexed with a light chain (κ or λ), or free light chains (FLCs) without a heavy chain component. Various PCDs have been described ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t06",
"wrapId":"1",
"children":[
"Table 6"
]
}
]
},
")"
]
},
". Note that an M spike denotes the presence of M protein, whereas IgM is immunoglobulin M."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_hm_t06"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_2",
"title":{
"__html":"Evaluation for Monoclonal Gammopathies"
},
"titleNode":{
"type":"section-title",
"hlId":"cb0052",
"children":[
"Evaluation for Monoclonal Gammopathies"
]
},
"children":[
{
"type":"p",
"hlId":"e8f930",
"children":[
"Evaluation for monoclonal gammopathies is typically restricted to patients with signs and symptoms, although a monoclonal gammopathy may also be identified incidentally with an elevated serum protein level on blood tests or during evaluation of neuropathy, vasculitis, or kidney injury ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t07",
"wrapId":"2",
"children":[
"Table 7"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_hm_t07"
]
},
{
"type":"p",
"hlId":"eb9690",
"children":[
"The M protein in PCDs can be detected by serum or urine protein electrophoresis (SPEP and UPEP), but isolated light chains (κ or λ) might be missed on protein electrophoresis. SPEP and UPEP are good initial screening tests to identify and quantify the presence of an M spike, and the serum FLC assay is a sensitive test to identify and quantify FLCs not bound to heavy chains in the serum. Neither SPEP nor UPEP can identify the subtype of immunoglobulin in the M spike, and both may miss small M proteins. Serum and urine immunofixation are more sensitive tests that can subtype the immunoglobulin. SPEP helps differentiate a monoclonal spike from a polyclonal spike, which are commonly seen with infections (e.g., hepatitis C virus, HIV), inflammatory processes, and chronic liver disease and do not usually require further hematologic evaluation. In inflammatory and infectious processes, κ and λ FLCs are increased, but proportionately, so the ratio remains normal. Patients with a PCD secrete one type of FLC, leading to an increase in the involved light chain and an abnormal FLC ratio."
]
},
{
"type":"p",
"hlId":"a4845e",
"children":[
"Although monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) are common causes of abnormal M proteins, other disorders can also produce an M spike (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t06",
"wrapId":"3",
"children":[
"Table 6"
]
}
]
},
")"
]
},
", and patients should be evaluated for the signs and symptoms of these diseases (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t07",
"wrapId":"3",
"children":[
"Table 7"
]
}
]
},
")"
]
},
". Tests considered during the evaluation of monoclonal gammopathies include complete blood count with differential; serum chemistries, including creatinine, calcium, and albumin levels; β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-microglobulin; SPEP; UPEP; serum and urine immunofixation; serum FLC tests; and quantitative immunoglobulins. Historically, plain radiographs of the bones (skeletal surveys) were used to determine the presence of lytic lesions in patients with MM. Bone scans, which detect increased osteoblast activity in most bone metastases, do not detect the purely lytic lesions in MM and are not useful. Commonly, PET scans and MRI are used to detect lytic bone lesions."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_hm_t06",
"mk19_b_hm_t07"
]
},
{
"type":"p",
"hlId":"04b722",
"children":[
"Bone marrow aspirate and biopsy quantify the percentage of plasma cells in the marrow and help classify the PCD. Cytogenetic evaluation of the bone marrow aspirate is important for prognosis. Bone marrow testing can be deferred in patients with low-risk features, such as an IgG gammopathy measuring less than 1.5 g/dL, a normal serum FLC ratio, and no evidence of end-organ damage."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"770254",
"children":[
"Tests necessary for the evaluation of monoclonal gammopathies include complete blood count with differential, serum chemistries, β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-microglobulin, serum and urine protein electrophoresis, serum and urine immunofixation, serum free light chain testing, and quantitative immunoglobulins."
]
},
{
"type":"keypoint",
"hlId":"131771",
"hvc":true,
"children":[
"Bone marrow evaluation need not be undertaken in patients with a monoclonal gammopathy and low-risk features, such as an IgG gammopathy less than 1.5 g/dL, normal serum free light chain ratio, and no end-organ damage."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_3",
"title":{
"__html":"Monoclonal Gammopathy of Undetermined Significance"
},
"titleNode":{
"type":"section-title",
"hlId":"3377bb",
"children":[
"Monoclonal Gammopathy of Undetermined Significance"
]
},
"children":[
{
"type":"p",
"hlId":"08e01e",
"children":[
"MGUS is characterized by an M protein level less than 3 g/dL (or less than 500 mg/24 h of urinary monoclonal FLCs), clonal plasma cells comprising less than 10% of the bone marrow cellularity, and the absence of related signs and symptoms of end-organ damage ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t08",
"wrapId":"4",
"children":[
"Table 8"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_hm_t08"
]
},
{
"type":"p",
"hlId":"6f5321",
"children":[
"The prevalence of MGUS increases with age, occurring in approximately 3% of persons older than 50 years and 5% of persons older than 70 years. When an asymptomatic condition has a high prevalence rate and low risk of progression to symptomatic disease, it is important to provide an accurate prognosis and appropriate counseling and management. The three types of MGUS, based on type of M protein, are non-IgM, IgM, and light chain. Non-IgM MGUS can progress to MM and, although less likely, to other PCDs at a rate of 1% per year. IgM MGUS has the potential to progress to Waldenström macroglobulinemia at a rate of 1.5% per year. Light-chain MGUS can progress to other PCDs at a rate of 0.3%. In addition to the type of M protein, factors that predict the risk of progression include the quantity of M protein and an abnormal serum FLC ratio ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t09",
"wrapId":"5",
"children":[
"Table 9"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_hm_t09"
]
},
{
"type":"p",
"hlId":"6af6e8",
"children":[
"Patients with MGUS are also at higher risk of osteoporosis and fracture of the axial skeleton, and bone mineral density testing should be considered. Patients also have shorter survival than matched controls."
]
},
{
"type":"p",
"hlId":"db357e",
"children":[
"Treatment is not required. Patients commonly undergo follow-up for signs and symptoms of progression, initially at 6 months and then yearly, if stable. Patients with low-risk MGUS can be clinically observed and do not require follow-up testing."
]
},
{
"type":"p",
"hlId":"c867b9",
"children":[
"Kidney disease in patients with monoclonal gammopathy has traditionally been linked to light-chain nephrotoxicity in those with MM or amyloid infiltration in those with amyloidosis. More recent data suggest that some patients with features otherwise consistent with MGUS may, nonetheless, have significant kidney disease related to the abnormal immunoglobulin. If other, more likely causes of kidney injury are excluded (e.g., diabetes or hypertension), these patients should be diagnosed with monoclonal gammopathy of renal significance, which requires myeloma-like therapy to prevent progressive and irreversible kidney injury."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"641ba5",
"children":[
"Monoclonal gammopathy of undetermined significance is characterized by an M protein level less than 3 g/dL, clonal plasma cells comprising less than 10% of the bone marrow cellularity, and the absence of related signs and symptoms of end-organ damage."
]
},
{
"type":"keypoint",
"hlId":"a4c5da",
"children":[
"Patients diagnosed with monoclonal gammopathy of renal significance require myeloma-like therapy to prevent progressive and irreversible kidney injury."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_4",
"title":{
"__html":"Multiple Myeloma"
},
"titleNode":{
"type":"section-title",
"hlId":"b494bb",
"children":[
"Multiple Myeloma"
]
},
"children":[
{
"type":"p",
"hlId":"9af120",
"children":[
"MM is a clonal plasma cell neoplasm. MM can manifest as smoldering (asymptomatic) disease with risk of progression or symptomatic disease, which requires immediate treatment to prevent complications. Smoldering MM has a higher clonal plasma cell burden than MGUS and a higher risk of transformation to MM requiring therapy."
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_4_1",
"title":{
"__html":"Clinical Manifestations and Findings"
},
"titleNode":{
"type":"section-title",
"hlId":"d7bef0",
"children":[
"Clinical Manifestations and Findings"
]
},
"children":[
{
"type":"p",
"hlId":"c89de5",
"children":[
"MM requiring therapy manifests with classic symptoms such as hypercalcemia, kidney disease, anemia, and bone disease (see CRAB and SLIM criteria in ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t08",
"wrapId":"6",
"children":[
"Table 8"
]
}
]
},
")"
]
},
". Other possible symptoms include fatigue, weight loss, neuropathy, and those arising from extramedullary plasmacytoma."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_hm_t08"
]
},
{
"type":"p",
"hlId":"ba3054",
"children":[
"Normocytic anemia is a common finding in MM requiring therapy. Anemia is caused by bone marrow plasma cell infiltration and kidney disease. The peripheral blood smear may show rouleaux formation. Patients can also be immunosuppressed from leukopenia, impaired lymphocyte function, and hypogammaglobulinemia (despite increased total immunoglobulin, normal immunoglobulins are reduced). Patients are at increased risk of respiratory infections, and chemotherapy for MM can further increase this risk."
]
},
{
"type":"p",
"hlId":"067cde",
"children":[
"Bone pain is a common symptom of MM. Osteoclast activation and osteoblast inactivation occur, leading to development of lytic lesions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f07",
"wrapId":"7",
"children":[
"Figure 7"
]
}
]
},
")"
]
},
" and vertebral body compression fracture. Patients with MM are prone to developing pathologic fractures with minimal or no trauma. The increased bone resorption (together with kidney dysfunction) leads to hypercalcemia. Kidney dysfunction is seen in a significant proportion of patients. The two main causes of kidney disease are elevated FLCs causing cast nephropathy and hypercalcemia. Cast nephropathy, commonly termed ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"myeloma kidney"
]
},
", is caused by deposition of FLCs in the distal tubules, leading to tubulointerstitial damage. Even with a normal baseline creatinine level, underlying cast nephropathy makes these patients especially vulnerable to additional kidney injury through dehydration, NSAID use, or exposure to radioiodine contrast. Other causes of kidney dysfunction in patients with MM include immunoglobulin light-chain amyloidosis, cryoglobulinemic glomerulonephritis, and proximal tubulopathy."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_hm_f07"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_4_2",
"title":{
"__html":"Diagnosis and Prognosis"
},
"titleNode":{
"type":"section-title",
"hlId":"2b6fde",
"children":[
"Diagnosis and Prognosis"
]
},
"children":[
{
"type":"p",
"hlId":"47d394",
"children":[
"Diagnostic criteria for MM are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t08",
"wrapId":"8",
"children":[
"Table 8"
]
}
]
},
". Evaluating patients with suspected MM includes identifying the M protein, assessing for symptoms of MM, and determining whether the symptoms are attributable to MM. Identification and quantification of the M protein are accomplished with SPEP, UPEP, and serum FLC testing (see Evaluation for Monoclonal Gammopathies previously). Bone marrow biopsy is performed to evaluate the plasma cell burden and to determine cytogenetics for risk stratification. All patients are evaluated for laboratory features of MM with complete blood count, serum creatinine and calcium levels, and imaging studies. Whole-body, low-dose CT (preferred) or PET-CT is recommended to detect lytic bone lesions in PCDs. If these modalities are negative, a whole-body MRI is recommended."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_hm_t08"
]
},
{
"type":"p",
"hlId":"fc63f9",
"children":[
"Symptoms of organ dysfunction should not necessarily be attributed to the underlying PCD. Kidney biopsy is performed to document myeloma kidney when it is clinically difficult to differentiate kidney injury from another diagnosis, such as diabetic nephropathy. Evaluation for alternative causes of hypercalcemia and anemia should be completed, especially when the patient has low-risk disease."
]
},
{
"type":"p",
"hlId":"59a232",
"children":[
"Smoldering MM has a risk of conversion to MM requiring therapy of about 10% per year for the first 5 years. The risk of progression decreases after the first 5 years. This risk is not uniform; risk factors for progression include a high M protein level, a large burden of clonal plasma cells, and an abnormal serum FLC ratio (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t09",
"wrapId":"9",
"children":[
"Table 9"
]
}
]
},
")"
]
},
". Patients with MM who are at imminent risk of progression in the next 2 years include those with 60% or more plasma cells in the bone marrow, more than one focal bone lesion on MRI, or a serum FLC ratio of 0.01 or less or 100 or greater. These patients generally require prompt treatment."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_hm_t09"
]
},
{
"type":"p",
"hlId":"e32181",
"children":[
"MM is staged based on the serum β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-microglobulin and albumin. However, bone marrow cytogenetics more accurately predict patient prognosis and guide better treatment decisions."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_4_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"adc7e7",
"children":[
"Patients with smoldering MM are usually monitored for progression to MM requiring therapy every 3 to 6 months. Studies have shown improved survival with early treatment of high-risk smoldering MM, including in those at imminent risk of progression as defined previously. However, defining additional categories of patients at high risk is somewhat controversial, and it is not routine practice to treat them. Bisphosphonates do not decrease the risk of progression to MM."
]
},
{
"type":"p",
"hlId":"e86f27",
"children":[
"Treatment of MM requiring therapy has been revolutionized over the last few years with the advent of new treatment options, which have significantly improved survival (averaging almost 10 years from diagnosis). Patients should initially be evaluated for autologous hematopoietic stem cell transplantation (HSCT) eligibility. Autologous HSCT with high-dose melphalan is not curative but does improve progression-free and overall survival. Patients eligible for transplant typically undergo induction therapy with multiagent chemotherapy followed by autologous HSCT and maintenance therapy. Induction chemotherapy involves various combinations of immunomodulatory drugs (lenalidomide), proteasome inhibitors (bortezomib), glucocorticoids (dexamethasone), alkylating agents (melphalan or cyclophosphamide), and monoclonal antibodies (daratumumab)."
]
},
{
"type":"p",
"hlId":"38cb84",
"children":[
"Treatment is not curative, so all patients eventually relapse or have refractory disease. Several drugs are used in this setting, including proteasome inhibitors (carfilzomib and ixazomib), immunomodulatory drugs (pomalidomide and, if not previously used, lenalidomide), histone deacetylase inhibitors (panobinostat), alkylating agents (bendamustine), and monoclonal antibodies (daratumumab, isatuximab, and elotuzumab). These agents are effective, and studies continue to evaluate the best combinations and sequencing."
]
},
{
"type":"p",
"hlId":"e3b79a",
"children":[
"Agents used to treat MM have unique adverse effects. MM increases the risk of venous thromboembolism, and lenalidomide further increases this risk. Patients should receive low-dose aspirin if they do not have additional risk factors; patients with additional risk factors may require thromboprophylaxis. Bortezomib and thalidomide cause peripheral neuropathy. Many medications (proteasome inhibitors, daratumumab, isatuximab, and elotuzumab) are associated with a high risk of herpes zoster reactivation, and prophylaxis with acyclovir is recommended."
]
},
{
"type":"p",
"hlId":"89785a",
"children":[
"Pain is a prominent symptom in patients with MM requiring therapy, and opioid treatment may be needed; NSAIDs can worsen kidney disease in these patients. Surgical stabilization of impending fracture is undertaken to prevent morbidity. Bisphosphonates (zoledronic acid and pamidronate) are used to prevent skeletal events. Zoledronic acid has also been shown to improve survival in patients with MM requiring therapy. Patients taking bisphosphonates should be closely monitored for kidney injury and osteonecrosis of the jaw. Patients should notify their dentist that they are receiving bisphosphonates and have dental work done before treatment initiation, if possible."
]
},
{
"type":"p",
"hlId":"bd4259",
"children":[
"Nephrotoxic agents and contrast studies should be used judiciously in patients with MM and a risk of worsening kidney disease. Hypercalcemia is treated with hydration and bisphosphonates. Annual influenza vaccination (inactivated) should be administered to all patients with MM. Because of the altered immune state associated with MM, pneumococcal vaccination with the 20-valent pneumococcal conjugate vaccine alone or 15-valent pneumococcal conjugate vaccine (PCV15) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) should be provided in accordance with Advisory Committee on Immunization Practices guidelines. Although the interval between PCV15 and subsequent PPSV23 is usually at least 1 year, a minimum of 8 weeks can be considered in patients with an immunocompromising condition such as MM (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3_2_2",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
"). Select patients with recurrent infections and hypogammaglobulinemia benefit from intravenous immune globulin infusions."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"dd4b05",
"children":[
"Hypercalcemia, kidney disease, anemia, and bone disease are classic symptoms of multiple myeloma requiring therapy, which is defined by the presence of an M protein and 10% or more clonal plasma or lymphoid cells in the bone marrow."
]
},
{
"type":"keypoint",
"hlId":"c38911",
"children":[
"Smoldering multiple myeloma is defined by monoclonal immunoglobulin levels and the percentage of plasma cells exceeding limits for monoclonal gammopathy of undetermined significance in patients with no disease-specific symptoms; most of these patients do not require immediate chemotherapy but should be closely monitored for disease progression."
]
},
{
"type":"keypoint",
"hlId":"365d4b",
"children":[
"Bisphosphonates should be routinely prescribed in patients with myeloma requiring therapy because they prevent skeletal events and improve survival."
]
},
{
"type":"keypoint",
"hlId":"4950ea",
"children":[
"Patients with multiple myeloma eligible for transplant typically receive induction therapy with multiagent chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance therapy."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_5",
"title":{
"__html":"Immunoglobulin Light-Chain Amyloidosis"
},
"titleNode":{
"type":"section-title",
"hlId":"b683e7",
"children":[
"Immunoglobulin Light-Chain Amyloidosis"
]
},
"children":[
{
"type":"p",
"hlId":"ee6cb7",
"children":[
"Amyloidosis refers to a varied group of disorders associated with extracellular deposition of low-molecular-weight proteins in a β-pleated sheet configuration. These are usually abnormal proteins that circulate in the blood and deposit in various organs. Various proteins have been implicated in amyloidosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t10",
"wrapId":"10",
"children":[
"Table 10"
]
}
]
},
")"
]
},
". All amyloid deposits have a characteristic apple-green birefringence under polarized light microscopy of the tissue with Congo red staining."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_hm_t10"
]
},
{
"type":"p",
"hlId":"2c5eb9",
"children":[
"Light-chain (AL) amyloidosis is the most common type. It is a clonal PCD characterized by production of amyloidogenic λ or κ FLCs. These light chains can deposit in the kidney, heart, skin, liver, and other organs. Skin manifestations are present in 30% to 40% of patients and include a generalized waxy appearance, easy bruising with minor pressure (pinch purpura), violaceous discoloration around the eyes (“raccoon eyes”), yellow waxy papules and plaques especially in a periorbital location ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f08",
"wrapId":"11",
"children":[
"Figure 8"
]
}
]
},
")"
]
},
", dystrophic nails, and macroglossia ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f09",
"wrapId":"11",
"children":[
"Figure 9"
]
}
]
},
")"
]
},
". Diagnosis requires biopsy of the affected tissue showing characteristic pathological findings. Abdominal fat pad or bone marrow biopsy may be preferred initially to avoid invasive biopsy. After amyloid in the tissue is confirmed, immunohistochemical staining can determine the light-chain composition of the amyloid deposit or identify alternative components, such as transthyretin or amyloid A protein. Patients with AL amyloidosis should undergo analysis for clonal PCDs with SPEP and UPEP, serum and urine immunofixation, serum FLC testing, bone marrow biopsy, and imaging."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_hm_f08",
"mk19_b_hm_f09"
]
},
{
"type":"p",
"hlId":"fc4379",
"children":[
"All patients are evaluated for extent of organ involvement. Cardiac involvement is common with AL amyloidosis, and evaluation typically includes echocardiography, electrocardiography, B-type natriuretic peptide, and serum troponin T. Cardiac MRI is more sensitive than echocardiography and has a distinctive pattern. Kidney involvement usually manifests as nephrotic range proteinuria; 24-hour urine protein quantitation or a urine protein-creatinine ratio assists diagnosis. Systemic amyloidosis with cutaneous involvement and cutaneous amyloidosis are characterized by extracellular deposition of altered amyloid protein in the skin, but the latter has a better prognosis, and patients may not require immediate therapy. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t11",
"wrapId":"12",
"children":[
"Table 11"
]
}
]
},
" lists other potentially involved organs and their clinical features."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_hm_t11"
]
},
{
"type":"p",
"hlId":"d64b8e",
"children":[
"Prognosis depends on the presence and extent of cardiac involvement; survival ranges from almost 8 years to only 6 months."
]
},
{
"type":"p",
"hlId":"5ea725",
"children":[
"Treatment starts with evaluating the patient for autologous HSCT. Eligibility for transplantation is based on performance status (independence completing activities of daily living) and the extent of organ involvement. Age is a less important factor, and some centers perform transplantation in patients up to age 80 years. Patients with advanced cardiac disease, stage 4 chronic kidney disease, or large pleural effusions are generally not eligible for transplantation. Autologous HSCT has been shown to improve organ function and survival. Patients ineligible for transplant should receive treatment with agents used for myeloma therapy. Supportive care to treat symptoms (such as diuretics for edema) is necessary."
]
},
{
"type":"p",
"hlId":"0722a2",
"children":[
"The second most common type of amyloidosis is transthyretin amyloid (wild-type or variant transthyretin, see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t10",
"wrapId":"13",
"children":[
"Table 10"
]
}
]
},
")"
]
},
", which deposits in the myocardium. It is estimated that wild-type transthyretin amyloidosis (previously senile systemic amyloidosis) may account for 10% of patients who have heart failure with preserved ejection fraction. Tafamidis is an oral agent shown to reduce mortality and improve quality of life in patients with transthyretin amyloid cardiomyopathy."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_hm_t10"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"b918f9",
"children":[
"Diagnosis of immunoglobulin light-chain amyloidosis requires biopsy of the affected tissue showing characteristic pathological findings of apple-green birefringence under polarized light microscopy of the tissue with Congo red staining; immunohistochemical staining then determines the light-chain nature of the amyloid."
]
},
{
"type":"keypoint",
"hlId":"3f240d",
"children":[
"Patients with immunoglobulin light-chain amyloidosis who are ineligible for autologous hematopoietic stem cell transplantation should receive treatment with agents used in multiple myeloma."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_6",
"title":{
"__html":"Waldenström Macroglobulinemia"
},
"titleNode":{
"type":"section-title",
"hlId":"94adf3",
"children":[
"Waldenström Macroglobulinemia"
]
},
"children":[
{
"type":"p",
"hlId":"48975d",
"children":[
"Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma with clonal lymphoplasmacytic cells in the bone marrow or lymph nodes that secrete clonal IgM into the blood. WM is differentiated from MGUS by the presence of more than 10% clonal lymphoplasmacytic cells in the bone marrow, greater than 3 g/dL of M protein, symptoms from the disease, or a combination of the three. As in MM, patients with smoldering, asymptomatic WM can be observed without therapy."
]
},
{
"type":"p",
"hlId":"c15c02",
"children":[
"Patients can present with classic “B symptoms” of drenching night sweats, fever, and weight loss and may have anemia and fatigue. Tissue infiltration leads to hepatosplenomegaly, lymphadenopathy, gastrointestinal dysfunction, and kidney disease. Peripheral sensorimotor neuropathy is seen in 20% of patients and can be associated with antimyelin-associated glycoprotein. Increased serum viscosity from the circulating IgM can lead to hyperviscosity syndrome, which can include diverse central nervous system symptoms, including headache, altered mental status, change in vision and hearing, nystagmus, and ataxia. Funduscopic evaluation may reveal dilated retinal veins, papilledema, and flame hemorrhages. Mucosal bleeding is related to platelet dysfunction and dysfibrinogenemia (prolonged thrombin time)."
]
},
{
"type":"p",
"hlId":"9bcb7d",
"children":[
"Symptomatic hyperviscosity requires emergent treatment with plasmapheresis to remove excess IgM. Therapy to decrease IgM production is instituted simultaneously in patients with hyperviscosity symptoms and should be initiated in other patients with symptomatic WM. Rituximab in combination with chemotherapy such as cyclophosphamide and bortezomib, along with glucocorticoids, is commonly used."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"32255b",
"children":[
"Patients with Waldenström macroglobulinemia with hyperviscosity syndrome, characterized by altered mental status and diverse central nervous system symptoms, dilated retinal veins on funduscopic examination, and mucosal bleeding from impaired platelet function and dysfibrinogenemia, require emergent plasmapheresis to remove excess IgM."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_7",
"title":{
"__html":"Cryoglobulinemia"
},
"titleNode":{
"type":"section-title",
"hlId":"d3c6cb",
"children":[
"Cryoglobulinemia"
]
},
"children":[
{
"type":"p",
"hlId":"025094",
"children":[
"Cryoglobulinemia denotes the presence of clonal or polyclonal immunoglobulins that precipitate in the serum at temperatures less than 37 °C (98.6 °F) and dissolve with rewarming. Cold agglutinins, which are often confused with cryoglobulins, are antibodies against erythrocyte antigens that agglutinate erythrocytes in blood at temperatures less than 37 °C (98.6 °F) and can sometimes cause cold agglutinin autoimmune hemolytic anemia."
]
},
{
"type":"p",
"hlId":"cbd906",
"children":[
"Cryoglobulinemia is classified as type I, II, or III based on the composition of the cryoglobulin. Type I involves a monoclonal immunoglobulin, usually IgM, and is associated with PCDs. Types II and III are called mixed cryoglobulinemias; they are composed of a mixture of polyclonal IgG and monoclonal or polyclonal IgM. Mixed cryoglobulinemias are usually seen in association with infections such as hepatitis C, with connective tissue disorders, and rarely with lymphoproliferative disorders."
]
},
{
"type":"p",
"hlId":"367586",
"children":[
"Type I is usually asymptomatic but can rarely cause symptoms of hyperviscosity and thrombosis. Patients can present with digital cyanosis, ulcers, Raynaud phenomenon, or gangrene. Patients with neurologic symptoms from hyperviscosity undergo emergent plasmapheresis, along with treatment of the underlying plasma cell dyscrasia to prevent cryoglobulin production. Vasculitic symptoms, such as palpable purpura, glomerulonephritis, and neuropathy, are less common in patients with type I (see ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s14_4_2_1",
"children":[
"MKSAP 19 Rheumatology"
]
},
" for further information on mixed cryoglobulinemias)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e9ca2b",
"children":[
"Type I cryoglobulinemia involves a monoclonal immunoglobulin (usually IgM), is associated with plasma cell dyscrasias, and patients are typically asymptomatic."
]
},
{
"type":"keypoint",
"hlId":"9f17e1",
"children":[
"Types II and III mixed cryoglobulinemias are composed of a mixture of polyclonal IgG and monoclonal or polyclonal IgM and are usually seen in association with hepatitis C, connective tissue disorders, or lymphoproliferative disorders."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s3_8",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32:1883-1898. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30038381",
"target":"_blank"
},
"children":[
"PMID: 30038381"
]
},
" doi:10.1038/s41375-018-0209-7"
]
},
{
"type":"reference",
"children":[
"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95:848-860. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32267020",
"target":"_blank"
},
"children":[
"PMID: 32267020"
]
},
" doi:10.1002/ajh.25819"
]
},
{
"type":"reference",
"children":[
"Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302-e312. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31162104",
"target":"_blank"
},
"children":[
"PMID: 31162104"
]
},
" doi:10.1016/S1470-2045(19)30309-2"
]
},
{
"type":"reference",
"children":[
"Kumar SK, Callander NS, Hillengass J, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. J Natl Compr Canc Netw. 2019;17:1154-1165. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31590151",
"target":"_blank"
},
"children":[
"PMID: 31590151"
]
},
" doi:10.6004/jnccn.2019.0049"
]
},
{
"type":"reference",
"children":[
"Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241-249. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29342381",
"target":"_blank"
},
"children":[
"PMID: 29342381"
]
},
" doi:10.1056/NEJMoa1709974"
]
},
{
"type":"reference",
"children":[
"Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29895887",
"target":"_blank"
},
"children":[
"PMID: 29895887"
]
},
" doi:10.1038/s41408-018-0077-4"
]
},
{
"type":"reference",
"children":[
"Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016;128:1321-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27432877",
"target":"_blank"
},
"children":[
"PMID: 27432877"
]
},
" doi:10.1182/blood-2016-04-711234"
]
},
{
"type":"reference",
"children":[
"Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30145929",
"target":"_blank"
},
"children":[
"PMID: 30145929"
]
},
" doi:10.1056/NEJMoa1805689"
]
},
{
"type":"reference",
"children":[
"Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35176010",
"target":"_blank"
},
"children":[
"PMID: 35176010"
]
},
" doi:10.15585/mmwr.mm7107a1"
]
},
{
"type":"reference",
"children":[
"van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30294326",
"target":"_blank"
},
"children":[
"PMID: 30294326"
]
},
" doi:10.3389/fimmu.2018.02134"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_hm_t06":{
"id":"mk19_b_hm_t06",
"number":6,
"bookId":"hm",
"title":{
"__html":"Disorders Associated With Monoclonal Gammopathies"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"39a7bf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 6. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t06"
}
]
},
"Disorders Associated With Monoclonal Gammopathies"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b0c8d",
"class":"col hd l",
"children":[
"Plasma Cell Disorders"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03a655",
"class":"cell txt l",
"children":[
"Monoclonal gammopathy of undetermined significance",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ea5c9",
"class":"cell txt l",
"children":[
"Multiple myeloma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dcace",
"class":"cell txt l",
"children":[
"Immunoglobulin light-chain (AL) amyloidosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"050e26",
"class":"cell txt l",
"children":[
"Monoclonal immunoglobulin deposition disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd688f",
"class":"cell txt l",
"children":[
"Proximal tubulopathy (with or without Fanconi syndrome); monoclonal gammopathy of renal significance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85ba4f",
"class":"cell txt l",
"children":[
"Solitary extramedullary or bone plasmacytoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8980ad",
"class":"cell txt l",
"children":[
"POEMS syndrome/osteosclerotic myeloma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"916b0e",
"class":"col hd l",
"children":[
"B-Cell Disorders"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01585f",
"class":"cell txt l",
"children":[
"Waldenström macroglobulinemia/lymphoplasmacytic lymphoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8be187",
"class":"cell txt l",
"children":[
"Marginal zone lymphoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f6151",
"class":"cell txt l",
"children":[
"Chronic lymphocytic leukemia/small lymphocytic lymphoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ae0af",
"class":"cell txt l",
"children":[
"Heavy chain disease"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"POEMS = polyneuropathy, organomegaly, endocrinopathy, presence of M protein, and skin changes."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Many diseases may be associated with monoclonal gammopathy of undetermined significance, including but not limited to connective tissue diseases, hepatitis C, HIV, cryoglobulinemia, and cold agglutinin disease."
]
]
},
"mk19_b_hm_t07":{
"id":"mk19_b_hm_t07",
"number":7,
"bookId":"hm",
"title":{
"__html":"Common Clinical Scenarios for Consideration of Plasma Cell Dyscrasia Testing<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c237bd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t07"
}
]
},
"Common Clinical Scenarios for Consideration of Plasma Cell Dyscrasia Testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f50f1a",
"class":"col hd l",
"children":[
"Clinical Scenario"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cdf329",
"class":"col hd l",
"children":[
"Disease Considerations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f0392",
"class":"col hd l",
"children":[
"Disease Characteristics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a97a9",
"class":"col hd l",
"children":[
"Additional Investigative Evaluation",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51e133",
"class":"cell txt l",
"children":[
"Lytic bone lesions or hypercalcemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad05f7",
"class":"cell txt l",
"children":[
"MM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fae8b3",
"class":"cell txt l",
"children":[
"Osteolytic bone lesions, PTH-independent hypercalcemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb91c4",
"class":"cell txt l",
"children":[
"Age-inappropriate bone loss",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a8550",
"class":"cell txt l",
"children":[
"MGUS, MM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d0e89",
"class":"cell txt l",
"children":[
"Osteopenia or osteoporosis with or without associated fractures"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"efb81f",
"class":"cell txt l",
"children":[
"Peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd59a2",
"class":"cell txt l",
"children":[
"AL amyloidosis; MM, WM (rare), MGUS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a43db",
"class":"cell txt l",
"children":[
"Sensorimotor axonal polyneuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d33d6",
"class":"cell txt l",
"children":[
"Tissue aspirate/biopsy for amyloid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2da0a5",
"class":"cell txt l",
"children":[
"POEMS syndrome; MGUS, MM, solitary plasmacytoma of bone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0725fa",
"class":"cell txt l",
"children":[
"Sensorimotor inflammatory demyelinating polyneuropathy, hepatosplenomegaly, endocrinopathies (hypogonadism, adrenal insufficiency), hyperpigmentation, hypertrichosis, multicentric Castleman disease, osteosclerotic bone lesions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49128a",
"class":"cell txt l",
"children":[
"VEGF measurement, endocrine evaluation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86fbcb",
"class":"cell txt l",
"children":[
"Cryoglobulinemic vasculitis; MGUS, MM, B-cell non-Hodgkin lymphoma (e.g., WM)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"913bfb",
"class":"cell txt l",
"children":[
"Sensory or sensorimotor polyneuropathy, mononeuropathy multiplex"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2244b5",
"class":"cell txt l",
"children":[
"Cryoglobulins, complement levels, hepatitis evaluation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bad2e0",
"class":"cell txt l",
"children":[
"Kidney disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9af2a",
"class":"cell txt l",
"children":[
"Cast nephropathy; MM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b05c82",
"class":"cell txt l",
"children":[
"Acute kidney injury, nonalbumin proteinuria (monoclonal FLCs), bland urine sediment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"674c46",
"class":"cell txt l",
"children":[
"Kidney biopsy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"733a4e",
"class":"cell txt l",
"children":[
"AL amyloidosis; MGUS, MM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d33d6",
"class":"cell txt l",
"children":[
"Tissue aspirate/biopsy for amyloid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"581880",
"class":"cell txt l",
"children":[
"Monoclonal gammopathy of renal significance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c32de",
"class":"cell txt l",
"children":[
"Varied kidney manifestations in patients who otherwise meet criteria for MGUS with a small plasma clone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"674c46",
"class":"cell txt l",
"children":[
"Kidney biopsy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3a93d",
"class":"cell txt l",
"children":[
"Proximal tubulopathy +/− Fanconi syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44f3af",
"class":"cell txt l",
"children":[
"Normal anion gap, hyperchloremic metabolic acidosis (proximal RTA), hypophosphatemia, hypouricemia, renal glucosuria, amino aciduria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2a50d",
"class":"cell txt l",
"children":[
"Kidney biopsy, serum phosphorus and uric acid, urinalysis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c80db5",
"class":"cell txt l",
"children":[
"Cryoglobulinemic vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94db11",
"class":"cell txt l",
"children":[
"Membranoproliferative glomerulonephritis with proteinuria and active urinary sediment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2244b5",
"class":"cell txt l",
"children":[
"Cryoglobulins, complement levels, hepatitis evaluation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc45c6",
"class":"cell txt l",
"children":[
"Anemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad05f7",
"class":"cell txt l",
"children":[
"MM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63ee51",
"class":"cell txt l",
"children":[
"Normocytic (occasionally macrocytic) anemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AL amyloidosis = immunoglobulin light-chain amyloidosis; FLC = free light chain; MGUS = monoclonal gammopathy of undetermined significance; MM = multiple myeloma; POEMS = polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes; PTH = parathyroid hormone; RTA = renal tubular acidosis; VEGF = vascular endothelial growth factor; WM = Waldenström macroglobulinemia."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"This is not an all-inclusive list; other less common conditions can be associated with plasma cell dyscrasias."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Evaluation beyond the standard evaluation for a monoclonal gammopathy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Premenopausal women or men <65 years of age with no additional risk factors for bone loss."
]
]
},
"mk19_b_hm_t08":{
"id":"mk19_b_hm_t08",
"number":8,
"bookId":"hm",
"title":{
"__html":"Diagnostic Criteria for the Plasma and Lymphoplasmacytic Cell Dyscrasias"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ec00a3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t08"
}
]
},
"Diagnostic Criteria for the Plasma and Lymphoplasmacytic Cell Dyscrasias"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"523223",
"class":"col hd l",
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57cd38",
"class":"col hd l",
"children":[
"M Protein"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7d322",
"class":"col hd l",
"children":[
"Bone Marrow Clonal Plasma Cells or Lymphoid Cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1bbad8",
"class":"col hd l",
"children":[
"Disease-Specific Signs/Symptoms"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6dfb7a",
"class":"cell txt l",
"children":[
"MGUS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2974bc",
"class":"cell txt li",
"children":[
"Non-IgM (IgG, IgA)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"895db7",
"class":"cell txt l",
"children":[
"<3 g/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6e9ef",
"class":"cell txt l",
"children":[
"<10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"159a06",
"class":"cell txt li",
"children":[
"IgM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"895db7",
"class":"cell txt l",
"children":[
"<3 g/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6e9ef",
"class":"cell txt l",
"children":[
"<10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8850f1",
"class":"cell txt li",
"children":[
"Light chain",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aede6c",
"class":"cell txt l",
"children":[
"Affected serum FLC increased and serum FLC ratio increased"
]
},
" ",
{
"type":"p",
"hlId":"4b35c0",
"class":"cell txt l",
"children":[
"Urinary M protein <500 mg/24 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6e9ef",
"class":"cell txt l",
"children":[
"<10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1e34a",
"class":"cell txt l",
"children":[
"Smoldering myeloma",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7af8e8",
"class":"cell txt l",
"children":[
"IgG or IgA ≥3 g/dL or κ or λ urinary FLC M protein ≥500 mg/24 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3fc32",
"class":"cell txt l",
"children":[
"10%-59%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c84f6",
"class":"cell txt l",
"children":[
"Smoldering WM",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa8f3f",
"class":"cell txt l",
"children":[
"IgM ≥3 g/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"87174b",
"class":"cell txt l",
"children":[
"≥10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d790d",
"class":"cell txt l",
"children":[
"Multiple myeloma requiring therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bf754",
"class":"cell txt l",
"children":[
"Present (absent in nonsecretory disease)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7ee1a",
"class":"cell txt l",
"children":[
"≥10% or biopsy evidence of a bony or extramedullary plasmacytoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"049f4c",
"class":"cell txt l",
"children":[
"WM requiring therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd058d",
"class":"cell txt l",
"children":[
"Present"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"87174b",
"class":"cell txt l",
"children":[
"≥10%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"7295b3",
"class":"col hd l",
"children":[
"CRAB Criteria for Myeloma-Related Signs and Symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"b89b65",
"class":"cell txt l",
"children":[
"HyperCalcemia: Serum calcium >11 mg/dL (2.8 mmol/L) or >1 mg/dL (0.3 mmol/L) higher than the upper limit of normal"
]
},
" ",
{
"type":"p",
"hlId":"851565",
"class":"cell txt l",
"children":[
"Renal failure: Serum creatinine >2 mg/dL (177 μmol/L) or creatinine clearance <40 mL/min"
]
},
" ",
{
"type":"p",
"hlId":"07a6c1",
"class":"cell txt l",
"children":[
"Anemia: Hemoglobin <10 g/dL (100 g/L) or 2 g/dL (20 g/L) below the lower limit of normal"
]
},
" ",
{
"type":"p",
"hlId":"303694",
"class":"cell txt l",
"children":[
"Bone disease: ≥1 lytic bone lesions on imaging studies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"194544",
"class":"col hd l",
"children":[
"SLIM Criteria for Myeloma-Defining Biomarkers"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ed4d7",
"class":"cell txt l",
"children":[
"≥60% clonal plasma cells on bone marrow examination (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"S"
]
},
"ixty)"
]
},
" ",
{
"type":"p",
"hlId":"ba0d14",
"class":"cell txt l",
"children":[
"Involved/uninvolved serum FLC ratio ≥100",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"LI"
]
},
"ght chains)"
]
},
" ",
{
"type":"p",
"hlId":"c28a3e",
"class":"cell txt l",
"children":[
"≥1 focal lesion on MRI (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"M"
]
},
"RI)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"58adf4",
"class":"col hd l",
"children":[
"WM-Related Signs and Symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f4c16",
"class":"cell txt l",
"children":[
"Systemic symptoms: Fatigue, B symptoms (fevers, night sweats, weight loss), neuropathy, hyperviscosity"
]
},
" ",
{
"type":"p",
"hlId":"32c74c",
"class":"cell txt l",
"children":[
"Physical examination findings: Symptomatic lymphadenopathy or hepatosplenomegaly"
]
},
" ",
{
"type":"p",
"hlId":"3a4ad0",
"class":"cell txt l",
"children":[
"Laboratory findings: Cytopenias (anemia, thrombocytopenia)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"FLC = free light chain; MGUS = monoclonal gammopathy of undetermined significance; WM = Waldenström macroglobulinemia."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Light-chain MGUS does not have a heavy-chain component."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Smoldering myeloma or WM may have the diagnostic M protein level with or without the percentage of bone marrow clonal plasma or lymphoid cells."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Involved light chain must be greater than 100 mg/L."
],
[
"Data from Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25439696",
"target":"_blank"
},
"children":[
"PMID: 25439696"
]
},
" doi:10.1016/S1470-2045(14)70442-5"
]
]
},
"mk19_b_hm_t09":{
"id":"mk19_b_hm_t09",
"number":9,
"bookId":"hm",
"title":{
"__html":"Mayo Clinic Model of Risk of MGUS Progression to a Clinically Symptomatic Plasma Cell Dyscrasia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f7544b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t09"
}
]
},
"Mayo Clinic Model of Risk of MGUS Progression to a Clinically Symptomatic Plasma Cell Dyscrasia"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"523223",
"class":"col hd l",
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d811a6",
"class":"col hd l",
"children":[
"Risk Factors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b97d93",
"class":"col hd l",
"children":[
"Progression"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a1d91",
"class":"cell txt l",
"children":[
"Non-light-chain MGUS (IgG, IgA, IgM)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6dad4f",
"class":"cell txt l",
"children":[
"M protein ≥1.5 g/dL"
]
},
" ",
{
"type":"p",
"hlId":"02dac6",
"class":"cell txt l",
"children":[
"Non-IgG M protein"
]
},
" ",
{
"type":"p",
"hlId":"03d436",
"class":"cell txt l",
"children":[
"Abnormal serum FLC ratio"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5303db",
"class":"cell txt l",
"children":[
"At 20 years:"
]
},
" ",
{
"type":"p",
"hlId":"74334d",
"class":"cell txt l",
"children":[
"3 RFs: 58% (high risk)"
]
},
" ",
{
"type":"p",
"hlId":"6ff2dd",
"class":"cell txt l",
"children":[
"2 RFs: 37% (high-intermediate risk)"
]
},
" ",
{
"type":"p",
"hlId":"e338e4",
"class":"cell txt l",
"children":[
"1 RF: 21% (intermediate-low risk)"
]
},
" ",
{
"type":"p",
"hlId":"6a90c7",
"class":"cell txt l",
"children":[
"0 RFs: 5% (low risk)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58c1c3",
"class":"cell txt l",
"children":[
"Smoldering myeloma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b41617",
"class":"cell txt l",
"children":[
"M protein ≥3 g/dL"
]
},
" ",
{
"type":"p",
"hlId":"33c173",
"class":"cell txt l",
"children":[
"Bone marrow plasma cells ≥10%"
]
},
" ",
{
"type":"p",
"hlId":"0d9b79",
"class":"cell txt l",
"children":[
"Serum FLC ratio <0.125 or >8 mg/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2c166",
"class":"cell txt l",
"children":[
"At 5 years:"
]
},
" ",
{
"type":"p",
"hlId":"1e9f64",
"class":"cell txt l",
"children":[
"3 RFs: 76%"
]
},
" ",
{
"type":"p",
"hlId":"0a1df2",
"class":"cell txt l",
"children":[
"2 RFs: 51%"
]
},
" ",
{
"type":"p",
"hlId":"bc76fa",
"class":"cell txt l",
"children":[
"1 RF: 25%"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"FLC = free light chain; MGUS = monoclonal gammopathy of undetermined significance; RF = risk factor."
],
[
"Data adapted from Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-17. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/15855274",
"target":"_blank"
},
"children":[
"PMID: 15855274"
]
},
" doi:10.1182/blood-2005-03-1038; and Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/17942755",
"target":"_blank"
},
"children":[
"PMID: 17942755"
]
},
" doi:10.1182/blood-2007-08-108357"
]
]
},
"mk19_b_hm_t10":{
"id":"mk19_b_hm_t10",
"number":10,
"bookId":"hm",
"title":{
"__html":"The Amyloidoses"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ab32b6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t10"
}
]
},
"The Amyloidoses"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1fa27",
"class":"col hd l",
"children":[
"Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8b7ed",
"class":"col hd l",
"children":[
"Disease Association"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf40a0",
"class":"col hd l",
"children":[
"Amyloid Protein"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d465c2",
"class":"cell txt l",
"children":[
"AL amyloidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd8032",
"class":"cell txt l",
"children":[
"Plasma cell dyscrasias (MGUS, multiple myeloma), Waldenström macroglobulinemia (rare)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef1a46",
"class":"cell txt l",
"children":[
"Monoclonal free λ or κ light chains"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90db24",
"class":"cell txt l",
"children":[
"Hereditary amyloidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0b517",
"class":"cell txt l",
"children":[
"Inherited"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d927e",
"class":"cell txt l",
"children":[
"Mutated TTR, fibrinogen α chain",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4894e5",
"class":"cell txt l",
"children":[
"AA amyloidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bdb208",
"class":"cell txt l",
"children":[
"Rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever, chronic infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9867ef",
"class":"cell txt l",
"children":[
"Serum amyloid A protein"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8cafba",
"class":"cell txt l",
"children":[
"Age-related (senile) amyloidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d8d2d",
"class":"cell txt l",
"children":[
"Age"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0898a9",
"class":"cell txt l",
"children":[
"Wild-type TTR"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9e75d",
"class":"cell txt l",
"children":[
"Dialysis-related amyloidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"505135",
"class":"cell txt l",
"children":[
"Dialysis for any reason"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e0e78",
"class":"cell txt l",
"children":[
"β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-microglobulin"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AA = amyloid A (secondary) amyloidosis; AL = immunoglobulin light-chain amyloidosis; MGUS = monoclonal gammopathy of undetermined significance; TTR = transthyretin."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Not an all-inclusive list."
]
]
},
"mk19_b_hm_t11":{
"id":"mk19_b_hm_t11",
"number":11,
"bookId":"hm",
"title":{
"__html":"Clinical Manifestations of AL Amyloidosis by Organ System"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"595c42",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t11"
}
]
},
"Clinical Manifestations of AL Amyloidosis by Organ System"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93da7a",
"class":"col hd l",
"children":[
"Organ System"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65ac9d",
"class":"col hd l",
"children":[
"Clinical Manifestations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df5415",
"class":"col hd l",
"children":[
"Findings"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ff2bb",
"class":"cell txt l",
"children":[
"Kidney"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2b537",
"class":"cell txt l",
"children":[
"Anasarca, lower extremity edema, foamy urine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70178b",
"class":"cell txt l",
"children":[
"Nephrotic range proteinuria with bland urine sediment, hypoalbuminemia, elevated serum creatinine, nephromegaly on kidney ultrasonography"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1405e2",
"class":"cell txt l",
"children":[
"Gastrointestinal bleeding, dysphagia, early satiety, abdominal distention, steatorrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2b682",
"class":"cell txt l",
"children":[
"Anemia, iron deficiency, submucosal hematomas on endoscopy, hypoalbuminemia, delayed gastric emptying, intestinal pseudo-obstruction, malabsorption, small intestinal bacterial overgrowth"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1a3cb",
"class":"cell txt l",
"children":[
"Liver"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c89d32",
"class":"cell txt l",
"children":[
"Weight loss, abdominal pain, features of chronic liver disease and portal hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3cadf",
"class":"cell txt l",
"children":[
"Cholestatic liver test abnormalities, hepatosplenomegaly, evidence of portal hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bd728",
"class":"cell txt l",
"children":[
"Neurologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97e1bd",
"class":"cell txt l",
"children":[
"Distal numbness, paresthesias, neuropathic pain, weakness, autonomic nerve dysfunction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a19e8",
"class":"cell txt l",
"children":[
"Distal sensorimotor polyneuropathy on electromyography/nerve conduction studies, autonomic neuropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d521f",
"class":"cell txt l",
"children":[
"Cardiac"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c1867",
"class":"cell txt l",
"children":[
"Chest pain, symptoms from chronic heart failure or arrhythmia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d1610",
"class":"cell txt l",
"children":[
"Echocardiographic changes (ventricular hypertrophy with granular appearance, restrictive cardiomyopathy with HFpEF more common than HFrEF), electrocardiographic changes (low voltages, pseudoinfarct pattern, conduction system changes, arrhythmias), abnormal cardiac MRI (late gadolinium enhancement)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b1f00",
"class":"cell txt l",
"children":[
"Coagulation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e01a5a",
"class":"cell txt l",
"children":[
"Bleeding diathesis, periorbital purpura, pinch purpura (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f08",
"wrapId":null,
"children":[
"Figure 8"
]
}
]
},
")"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de5f8b",
"class":"cell txt l",
"children":[
"Factor X deficiency with prolonged PT and aPTT, prolonged PT and aPTT from advanced liver impairment, blood vessel fragility from vascular amyloid deposition"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b3d4d",
"class":"cell txt l",
"children":[
"Musculoskeletal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d4e46",
"class":"cell txt l",
"children":[
"Macroglossia (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f09",
"wrapId":null,
"children":[
"Figure 9"
]
}
]
},
")"
]
},
", muscle pseudohypertrophy, symmetric arthropathy, submandibular gland enlargement, carpal tunnel syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64dcda",
"class":"cell txt l",
"children":[
"Impaired median nerve conduction across the carpal tunnel, joint space widening on plain radiographs, periarticular soft tissue and muscle infiltration on MRI"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"aPTT = activated partial thromboplastin time; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; PT = prothrombin time."
]
]
}
}
}